Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Guselkumab is a biologic medicine sold under the brand name Tremfya. It treats moderate to severe plaque psoriasis, active psoriatic arthritis, and certain cases of ulcerative colitis or Crohn's disease. Approved ages and dosing depend on the condition.
read more about guselkumab ...Guselkumab binds to part of interleukin-23, a protein involved in inflammation. Blocking this signal reduces inflammatory activity. Treatment aims to control the symptoms and inflammation of the condition for which it is prescribed.
Guselkumab can be injected under the skin. For ulcerative colitis or Crohn's disease, an intravenous infusion or under-the-skin injections can be used for the initial treatment phase. Your clinician will set a schedule based on the condition and treatment phase.
Respiratory infections, headache, and injection-site reactions are reported side effects. Guselkumab can increase the risk of infections. Tell your care team about signs of infection or an allergic reaction.
Your clinician will evaluate you for tuberculosis before treatment. Liver tests are part of care for people treated for ulcerative colitis or Crohn's disease. Review vaccinations with your care team, since live vaccines should be avoided during treatment.
Guselkumab is sold as Tremfya. Its dosing varies by condition.
Yes. It is approved for adults with moderately to severely active Crohn's disease.
Its plaque psoriasis and psoriatic arthritis indications include patients at least 6 years old who weigh at least 40 kilograms. The ulcerative colitis and Crohn's disease indications are for adults.
Yes. The label directs clinicians to evaluate patients for tuberculosis before starting guselkumab.
Guselkumab (subcutaneous route) - Side effects & dosage. Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/guselkumab-subcutaneous-route/description/drg-20406359. Date Accessed October 6, 2026.
Guselkumab Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a617036.html. Date Accessed October 6, 2026.
TREMFYA - Use in Pediatric Patients with Plaque Psoriasis or Psoriatic Arthritis. Johnson & Johnson. https://www.jnjmedicalconnect.com/products/tremfya/medical-content/tremfya-use-in-pediatric-patients-with-plaque-psoriasis-or-psoriatic-arthritis. Date Accessed October 6, 2026.
TREMFYA- guselkumab injection. DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6dc9ae-1c4c-42d9-87aa-c315ecc51b56. Date Accessed October 6, 2026.
U.S. FDA approves TREMFYA? (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor. Johnson & Johnson. https://www.jnj.com/media-center/press-releases/u-s-fda-approves-tremfya-guselkumab-for-the-treatment-of-pediatric-plaque-psoriasis-and-active-psoriatic-arthritis-marking-a-first-and-only-approval-for-an-il-23-inhibitor. Date Accessed October 6, 2026.